High-dose olanzapine for treatment-resistant schizophrenia.
Roth
Bryan L
BL
Department of Pharmacology, Medicinal Chemistry and Psychiatry, University of North Carolina at Chapel Hill School of Medicine, NC 27599, USA. bryan_roth@med.unc.edu
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D003024:Clozapine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D000077152:Olanzapine; D020641:Polymorphism, Single Nucleotide; D016032:Randomized Controlled Trials as Topic; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D013810:Therapeutic Equivalency
D014150:Antipsychotic Agents; D044402:Receptor, Serotonin, 5-HT2A; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine